Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
about
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.Brodalumab: First Global Approval.Brodalumab for the treatment of psoriasis.Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
P2860
Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@en
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@nl
type
label
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@en
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@nl
prefLabel
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@en
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@nl
P2093
P2860
P356
P1476
Long-term clinical safety and ...... te-to-severe plaque psoriasis.
@en
P2093
H Nakagawa
Japanese Brodalumab Study Group
P2860
P304
P356
10.1111/JDV.13785
P577
2016-06-29T00:00:00Z